Social Media Ideas for Revance

‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead mov...

FDA Approves RHA Redensity Eye for Infraorbital Volume Deficiencies

FDA approves RHA Redensity Eye for correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults ages 22 and older.

Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan

FDA extends review of Capricor cell therapy; Pain drug startup to go public

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the pub...

Recursion (RXRX) Q2 2026 Earnings Call Transcript

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

Q32 bounces back to claim study success for alopecia drug

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations. 

FACTOR X Emerges from Stealth with Novel RNA - based Technology to Transform the Global Beauty Industry

FACTOR X is a newly launched longevity-focused beauty technology company developing a breakthrough cellular delivery platform designed to transform the anti-aging skincare industry...

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies

ADARx has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA medicines.

Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claime...